Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Piliè on the Benefit of Second-Generation AR Inhibitors in Nonmetastatic CRPC

April 6th 2021

Patrick Piliè, MD, discusses the benefit of second-generation androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Shore on Future Research Directions with Darolutamide in Prostate Cancer

April 1st 2021

Neal D. Shore, MD, FACS, discusses future research directions with darolutamide for the treatment of patients with prostate cancer.

OncLive® Takes a Look Back at Most Listened Podcasts of 2020

April 1st 2021

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Novel NTD Inhibitor EPI-7386 Plus Enzalutamide Under Evaluation in mCRPC

March 31st 2021

The first-in-class N-terminal domain androgen receptor inhibitor EPI-7386 is being examined in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer as part of a phase 1/2 trial.

Enzalutamide Granted Positive EU Opinion for Metastatic Hormone-Sensitive Prostate Cancer

March 30th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion to recommend an additional indication of enzalutamide for the treatment of adult patients with metastatic hormone-sensitive prostate cancer.

177Lu-PSMA-617 Improves OS and rPFS Over Best Standard of Care in Advanced Prostate Cancer

March 23rd 2021

The addition of the targeted radioligand therapy 177Lu-PSMA-617 to best standard of care was found to significantly improve overall survival and radiographic progression-free survival over best standard care alone in patients with prostate specific membrane antigen–positive metastatic castration-resistant prostate cancer, meeting both primary end points of the phase 3 VISION trial.

Dr. Dorff on the Importance of Somatic Testing in mCRPC

March 22nd 2021

Tanya Dorff, MD, discusses the importance of somatic testing in metastatic castration-resistant prostate cancer.

PARP Inhibitors, Novel Combos Represent the Future in Metastatic CRPC

March 16th 2021

PARP inhibitors and novel combinations targeting the androgen receptor will help define the future treatment paradigm for patients with metastatic castration-resistant prostate cancer.

Bipolar Androgen Therapy Demonstrates Comparable Efficacy With Enzalutamide in mCRPC

March 11th 2021

Bipolar androgen therapy demonstrated clinically meaningful activity and a good safety profile compared with enzalutamide in asymptomatic men with metastatic castration-resistant prostate cancer who progressed on abiraterone acetate.

Advanced Prostate Cancer: Remaining Challenges

March 9th 2021

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.

Risk Factors in Advanced Prostate Cancer

March 9th 2021

Stephen Freedland, MD, discusses risk factors involved in men with advanced prostate cancer who receive androgen deprivation therapy.

NICE Recommends Against Olaparib for Metastatic Prostate Cancer

March 8th 2021

The United Kingdom’s National Institute for Health and Care Excellence will not recommend olaparib for the treatment of patients with hormone-relapsed, metastatic prostate cancer that harbors BRCA1 or BRCA2 mutations that has progressed on abiraterone acetate or enzalutamide.

Advanced Prostate Cancer: New Findings From ASCO GU 2021

March 8th 2021

Dan George, MD, reviews new findings in advanced prostate cancer presented at ASCO GU 2021.

The First Oral GNRH Receptor Antagonist for Advanced Prostate Cancer

March 8th 2021

Neal Shore, MD, discusses the recent FDA approval of the first oral GNRH receptor antagonist, relugolix, for men with advanced prostate cancer, along with data from the phase 3 HERO trial.

Launch of ARANOTE Study Augments Development Program for Darolutamide in Prostate Cancer

March 3rd 2021

Darolutamide plus ADT will be evaluated versus ADT alone in patients with metastatic hormone-sensitive prostate cancer in the phase 3 ARANOTE study as part Bayer and Orion Corporation’s growing clinical development program for the oral AR inhibitor in prostate cancer.

Rapid Readouts: Final Analysis Results From the Phase 3 TITAN Study

March 3rd 2021

Kim N. Chi, MD, presents slides from the 2021 ASCO Genitourinary Cancers Symposium for the final results from the phase 3 TITAN study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy.

Dr. Klein on the Safety of VERU-111 in mCRPC

February 17th 2021

Eric Klein, MD, discusses safety data with VERU-111 from a phase 2 trial that enrolled patients with metastatic castration-resistant prostate cancer that was presented during the 2021 Genitourinary Cancers Symposium.

Molecular Signatures Linked With Long-Term Response to Apalutamide in Nonmetastatic CRPC

February 13th 2021

February 13, 2021 - Certain molecular signatures at baseline were found to be independently linked with long-term response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

Reduction in PSA Screening Associated with Increased Incidence of Metastatic Prostate Cancer in the United States

February 13th 2021

February 13, 2021 - Reductions in prostate-specific antigen screening are likely responsible for the recent increase in metastatic prostate cancer cases in the United States.

Dr. Piliè on Impact of Adiposity on Response to Androgen Signaling Inhibition in mCRPC

February 13th 2021

Patrick Pilie, MD, discusses the impact of adiposity on response to androgen signaling inhibition in patients with metastatic castration-resistant prostate cancer.